Cytiva's sustainability plan
2022 Performance highlights

“73% of biological therapies (used for vaccinations and immune related disease treatments) that were newly approved in 2022 were supported by a solution from Cytiva.”

Carbon offsets illustration
We support the UNGC and SDGs
We support the UN SDGs